FRISCO, Texas, May 11, 2012 /PRNewswire/ -- SomnoMed  (SOM.AX) - expects shipment of its 100,000th SomnoDent® apnea appliance case since the inception of the company in June 2012. This important company milestone is anticipated to occur whilst SomnoMed attends the annual Associated Professional Sleep Societies (APSS) conference in Boston.

"This is a significant milestone for us as it demonstrates continued strong demand for SomnoDent® sleep apnea treatment," said Ralf Barschow, President & CEO of SomnoMed. "With more than 100,000 patients and counting we are continuing to grow and expand the products and services associated with SomnoDent sleep apnea treatment."

We look forward to announcing further details associated with this 100,000 treatment in June.

About SomnoMed

SomnoMed is a public company (SOM.AX) providing diagnostic and treatment solutions for Sleep Breathing Disorders such as Obstructive Sleep Apnea. SomnoMed was commercialized on the basis of extensive clinical research. Supporting independent clinical research, continuous innovation and instituting medical manufacturing standards has resulted in SomnoDent® becoming the state-of-the-art and clinically proven medical oral appliance therapy for obstructive sleep apnea. For additional information, visit SomnoMed at www.somnomed.com.

Contact:

Anthony White

+1-972-978-4906

awhite@somnomed.com

SOURCE SomnoMed

Copyright 2012 PR Newswire

Somnomed (ASX:SOM)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Somnomed Charts.
Somnomed (ASX:SOM)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Somnomed Charts.